

Special Issue

Monitoring Anticoagulant

Message from the Guest Editor

This Special Issue, "Monitoring Anticoagulants", aims to update laboratory monitoring practice for current anticoagulants and those more recently introduced, and which require a much lighter survey, except for some well-defined cases at risk of bleeding or thrombosis recurrence. Since the introduction of the first anticoagulant treatments, Vitamin K antagonists and Heparins, the prognosis of thrombotic diseases has been revolutionized. A wide variety of anticoagulants or antithrombotics have been introduced these past years, and requirements for therapy monitoring are highly dependent on the drug. The major associated clinical risks concern occurrence of hemorrhages, whose incidence depends on the patient's clinical state and drug dosage adjustment. As major bleedings are life-threatening, when present, anticoagulation needs to be reversed without delay. Monitoring efficacy of this reversal is part of the follow-up of anticoagulant therapy.

Guest Editor

Dr. Jean Amiral

Scientific Director (SH-Consulting) and consultant (HYPHEN BioMed and Sysmex Corp.), Andrésey, France

Deadline for manuscript submissions

closed (31 January 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/31758

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).